WO2004083389A3 - Mbcats as modifiers of the beta-catenin pathway and methods of use - Google Patents

Mbcats as modifiers of the beta-catenin pathway and methods of use Download PDF

Info

Publication number
WO2004083389A3
WO2004083389A3 PCT/US2004/007626 US2004007626W WO2004083389A3 WO 2004083389 A3 WO2004083389 A3 WO 2004083389A3 US 2004007626 W US2004007626 W US 2004007626W WO 2004083389 A3 WO2004083389 A3 WO 2004083389A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
methods
mbcats
modifiers
catenin pathway
Prior art date
Application number
PCT/US2004/007626
Other languages
French (fr)
Other versions
WO2004083389A2 (en
Inventor
Helen Francis-Lang
Christopher G Winter
Richard Benn Abegania Ventura
Lynn Margaret Bjerke
Haiguang Zhang
Joanne I Adamkewicz
Bing Hai
Kim Lickteig
Monique Nicoll
Original Assignee
Exelixis Inc
Helen Francis-Lang
Christopher G Winter
Richard Benn Abegania Ventura
Lynn Margaret Bjerke
Haiguang Zhang
Joanne I Adamkewicz
Bing Hai
Kim Lickteig
Monique Nicoll
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Helen Francis-Lang, Christopher G Winter, Richard Benn Abegania Ventura, Lynn Margaret Bjerke, Haiguang Zhang, Joanne I Adamkewicz, Bing Hai, Kim Lickteig, Monique Nicoll filed Critical Exelixis Inc
Publication of WO2004083389A2 publication Critical patent/WO2004083389A2/en
Publication of WO2004083389A3 publication Critical patent/WO2004083389A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Human MBCAT genes are identified as modulators of the beta-catenin pathway, and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin, comprising screening for agents that modulate the activity of MBCAT are provided.
PCT/US2004/007626 2003-03-13 2004-03-12 Mbcats as modifiers of the beta-catenin pathway and methods of use WO2004083389A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US45446903P 2003-03-13 2003-03-13
US60/454,469 2003-03-13
US47072803P 2003-05-14 2003-05-14
US60/470,728 2003-05-14
US47976903P 2003-06-19 2003-06-19
US47979503P 2003-06-19 2003-06-19
US60/479,769 2003-06-19
US60/479,795 2003-06-19

Publications (2)

Publication Number Publication Date
WO2004083389A2 WO2004083389A2 (en) 2004-09-30
WO2004083389A3 true WO2004083389A3 (en) 2006-10-12

Family

ID=33033289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007626 WO2004083389A2 (en) 2003-03-13 2004-03-12 Mbcats as modifiers of the beta-catenin pathway and methods of use

Country Status (1)

Country Link
WO (1) WO2004083389A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLAPPER ET AL.: "Beta-Catenin-Mediated Signaling: A Molecular Target for Early Chemopreventive Intervention", MUTAT. RES., vol. 555, no. 1-2, November 2004 (2004-11-01), pages 97 - 105, XP004598062, DOI: doi:10.1016/j.mrfmmm.2004.05.021 *
LU ET AL.: "Isoprenylcysteine Carboxyl Methyltransferase Modulates Endothelial Monolayer Permeability: Involvement of RhoA Carboxyl Methylation", CIRC. RES., vol. 94, no. 3, February 2004 (2004-02-01), pages 306 - 315 *
OLOUNI ET AL.: "Modulation of Wnt3a-Mediated Nuclear Beta-Catenin Accumulation and Activation by Integrin-Linked Kinase in Mammalian Cells", ONCOGENE, 26 June 2006 (2006-06-26) *

Also Published As

Publication number Publication date
WO2004083389A2 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2003083047A3 (en) MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2006009947A3 (en) Migfs as modifiers of the igf pathway and methods of use
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2006009928A3 (en) Galnts as modifiers of the igfr pathway and methods of use
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2005002418A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2005003297A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2005090992A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2005017121A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004005483A3 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2004065542A3 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004083447A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004005486A3 (en) Mp21s as modifiers of the p21 pathway and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2004047761A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase